Comparative Pharmacology
Head-to-head clinical analysis: ALAWAY versus ALCAFTADINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALAWAY versus ALCAFTADINE.
ALAWAY vs ALCAFTADINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALAWAY (cetirizine ophthalmic solution) is a selective histamine H1-receptor antagonist that inhibits histamine release from mast cells, reducing ocular itching and allergic conjunctivitis symptoms.
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.
2 doses (each dose = 2 sprays) per nostril, repeated every 12 hours as needed. Each spray delivers 50 mg of sodium cromoglicate. Route: intranasal. Maximum: 2 doses per nostril per day.
1 drop of 0.25% ophthalmic solution in each affected eye twice daily.
None Documented
None Documented
Terminal elimination half-life of 3-4 hours in healthy adults; extended to 10-15 hours in severe renal impairment (CrCl <30 mL/min). Clinical context: Twice-daily dosing is standard; dose adjustment required in renal insufficiency.
Clinical Note
moderateAlcaftadine + Betahistine
"The therapeutic efficacy of Betahistine can be decreased when used in combination with Alcaftadine."
Clinical Note
moderateAmphetamine + Alcaftadine
"Amphetamine may decrease the sedative activities of Alcaftadine."
Clinical Note
moderateDiethylpropion + Alcaftadine
"Diethylpropion may decrease the sedative activities of Alcaftadine."
Clinical Note
moderatePhentermine + Alcaftadine
Terminal elimination half-life is approximately 2 hours (range 1.5–3 h) after topical ocular administration, appropriate for twice-daily dosing.
Primarily renal excretion (80-90% unchanged drug) via glomerular filtration and active tubular secretion; 10-20% fecal excretion. Minimal biliary elimination.
Primarily renal (approximately 50% unchanged), with the remainder as metabolites; negligible biliary/fecal elimination.
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine
"Phentermine may decrease the sedative activities of Alcaftadine."